These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19549089)

  • 21. The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.
    Burns PR; Kim ED; Ruff DD; Seftel AD
    Am J Mens Health; 2018 May; 12(3):524-530. PubMed ID: 26438471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    Aging Male; 2012 Mar; 15(1):14-21. PubMed ID: 22092151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Morgentaler A
    Int J Impot Res; 2008; 20(3):331; author reply 332. PubMed ID: 18475269
    [No Abstract]   [Full Text] [Related]  

  • 24. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
    Blick G; Khera M; Bhattacharya RK; Nguyen D; Kushner H; Miner MM
    Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males.
    Schrader S; Mills A; Scheperle M; Block JE
    Clin Cornerstone; 2005; 7 Suppl 4():S26-31. PubMed ID: 16651205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.
    Taylor F; Levine L
    J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sexual functioning and satisfaction in nonresponders to testosterone gel: Potential effectiveness of retreatment in hypogonadal males.
    Steidle C; Witt MA; Matrisciano J; Block JE
    Clin Cornerstone; 2005; 7 Suppl 4():S20-5. PubMed ID: 16651204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.
    Meikle AW; Matthias D; Hoffman AR
    BJU Int; 2004 Apr; 93(6):789-95. PubMed ID: 15049991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A; Norwood P; Potts S; Gould E; Chitra S
    J Sex Med; 2014 Mar; 11(3):857-64. PubMed ID: 24283410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new 2% testosterone gel formulation: a comparison with currently available topical preparations.
    Arver S; Stief C; de la Rosette J; Jones TH; Neijber A; Carrara D
    Andrology; 2018 May; 6(3):396-407. PubMed ID: 29600542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L; Lazarou S; Morgentaler A
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of a single serum testosterone measurement to determine response to topical testosterone replacement in hypogonadal men.
    Muram D; Ni X
    Curr Med Res Opin; 2016; 32(2):263-9. PubMed ID: 26549704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
    Morgentaler A; McGettigan J; Xiang Q; Danoff TM; Gould EM
    Int J Impot Res; 2015; 27(2):41-5. PubMed ID: 25056809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of testosterone gel in the treatment of male hypogonadism.
    Lakshman KM; Basaria S
    Clin Interv Aging; 2009; 4():397-412. PubMed ID: 19966909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).
    Bhattacharya RK; Khera M; Blick G; Kushner H; Nguyen D; Miner MM
    BMC Endocr Disord; 2011 Nov; 11():18. PubMed ID: 22044661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
    Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
    Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.